Organon & Co.OGNEarnings & Financial Report
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
OGN Q1 FY2026 Key Financial Metrics
Revenue
$1.5B
Gross Profit
$783.0M
Operating Profit
N/A
Net Profit
$146.0M
Gross Margin
53.6%
Operating Margin
N/A
Net Margin
10.0%
YoY Growth
-3.5%
EPS
$0.55
Organon & Co. Q1 FY2026 Financial Summary
Organon & Co. reported revenue of $1.5B (down 3.5% YoY) for Q1 FY2026, with a net profit of $146.0M (up 67.8% YoY) (10.0% margin). Cost of goods sold was $677.0M.
Key Financial Metrics
| Total Revenue | $1.5B |
|---|---|
| Net Profit | $146.0M |
| Gross Margin | 53.6% |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Organon & Co. Q1 FY2026 revenue of $1.5B breaks down across 3 segments, led by Established Brands at $880.0M (60.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Established Brands | $880.0M | 60.3% |
| Women’s Health | $389.0M | 26.6% |
| Biosimilars | $173.0M | 11.8% |
Organon & Co. Annual Revenue by Year
Organon & Co. annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.2B).
Organon & Co. Quarterly Revenue & Net Profit History
Organon & Co. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.5B | -3.5% | $146.0M | 10.0% |
| Q4 FY2025 | $1.5B | -5.3% | $-205.0M | -13.6% |
| Q3 FY2025 | $1.6B | +1.3% | $160.0M | 10.0% |
| Q2 FY2025 | $1.6B | -0.8% | $145.0M | 9.1% |
| Q1 FY2025 | $1.5B | -6.7% | $87.0M | 5.8% |
| Q4 FY2024 | $1.6B | -0.4% | $109.0M | 6.8% |
| Q3 FY2024 | $1.6B | +4.1% | $359.0M | 22.7% |
| Q2 FY2024 | $1.6B | -0.1% | $195.0M | 12.1% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.61B | $1.58B | $1.59B | $1.51B | $1.59B | $1.60B | $1.51B | $1.46B |
| YoY Growth | -0.1% | 4.1% | -0.4% | -6.7% | -0.8% | 1.3% | -5.3% | -3.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.15B | $12.75B | $13.10B | $13.16B | $13.50B | $13.55B | $12.87B | N/A |
| Liabilities | $12.01B | $12.26B | $12.63B | $12.61B | $12.77B | $12.65B | $12.12B | N/A |
| Equity | $144.0M | $493.0M | $472.0M | $542.0M | $733.0M | $906.0M | $752.0M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $332.0M | $141.0M | $390.0M | $75.0M | $220.0M | $264.0M | $141.0M |